Contact information
Colleges
Michael Desborough
BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil
Consultant Haematologist & Honorary Senior Lecturer
The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.
Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.
I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).
Key publications
-
Desmopressin use for minimising perioperative blood transfusion.
Journal article
Desborough MJ. et al, (2017), Cochrane Database Syst Rev, 7
-
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Journal article
Desborough MJR. et al, (2017), J Thromb Haemost, 15, 263 - 272
-
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.
Journal article
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
-
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Journal article
Thomas W. et al, (2021), J Thromb Haemost
-
Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data.
Conference paper
Schofield J. et al, (2022), Br J Haematol
-
Real-World Evidence of Caplacizumab Use in the Management of Acute TTP.
Journal article
Dutt T. et al, (2020), Blood
Recent publications
-
Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura.
Journal article
Aggarwal A. et al, (2023), British journal of haematology
-
Antiplatelet Resistance: A Review of Concepts, Mechanisms, and Implications for Management in Acute Ischemic Stroke and Transient Ischemic Attack
Journal article
Krishnan K. et al, (2023), Stroke: Vascular and Interventional Neurology
-
Real world reduction in red cell transfusion with restrictive transfusion threshold in haematology inpatients
Journal article
Pervaiz O. et al, (2023), Transfusion Medicine
-
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.
Journal article
Bye AP. et al, (2022), Haematologica
-
Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data.
Conference paper
Schofield J. et al, (2022), Br J Haematol
ORCID
0000-0002-1951-5616